CompletedEUCTR 2006-004783-31
A Double-Blind, Randomised, Parallel-Group, Placebo-Controlled, MultiCentre, Phase IIa Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Ascending Multiple Oral Dos...
This historical record does not confirm current site availability.
Historical research recordHungary + LatviaSchizophrenia
Understand this study
What did researchers investigate?
This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments. Check the source details below for country statuses and any transfer to CTIS.
- Listed locations
- Hungary · Latvia
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Study information
Study start dateNot clearly listed
- Recruitment status
- Completed
- Enrollment listed in the registry
- 80
- Sponsor
- AstraZeneca AB
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- Hungary, Latvia
- Age range
- Not clearly listed
- Official registry ID
- EUCTR 2006-004783-31
- Official title
Show the full official title
A Double-Blind, Randomised, Parallel-Group, Placebo-Controlled, MultiCentre, Phase IIa Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Ascending Multiple Oral Dos...
Get this study by email
Recruitment & locations
CompletedHungary · Latvia
Questions about this study
Who is behind this study?
The study sponsor is AstraZeneca AB.
